Experimental cancer combo tested in tiny, terminated trial

NCT ID NCT05571969

Terminated Disease control Sponsor: Allarity Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no conclusions about effectiveness can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 2X-121 (a PARP inhibitor) and dovitinib (a targeted cancer drug)
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This was a very early (Phase 1) safety study that was terminated early with only 14 participants. The drugs may cause significant side effects, and it is unknown if they will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Carolina BioOncology

Huntersville, North Carolina, 28078, United States
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.